Introduction
Nitric oxide (NO) plays an important role in the regulation of vascular tone and blood pressure, in the neuronal transmission as well as in the apoptosis processes and in the modulation of immunological and inflammatory reactions (Moncada et al., 1991; Nathan, 1992; Schulz & Triggle, 1994; Lloyd-Jones & Bloch, 1996) . Recently, it was shown that the nitric oxide pathway is present in human platelets (Radomski et al., 1990; Malinski et al., 1993; Muruganandam & Mutus, 1994; Zhou et al., 1995) . NO was found to inhibit platelet aggregation through the activation of the soluble guanylate cyclase (Mellion et al., 1981; Radomski et al., 1990) . Until now, NO effects on platelet aggregation and/or Ca2+ mobilization stimulated by different agonists have been studied by using NO-donors such as sodium nitroprusside (SNP), 3-morpholino-sydnonimine-hydrochloride (SIN-1) or nitroglycerin (NTG) (Mellion et al., 1981; Gerzer et al., 1988; Astarie et al., 1992; Amano et al., 1994) . These compounds released NO spontaneously or after transformation. The antiaggregatory properties and vasodilator action of these NO-donors were widely accepted for their beneficial effects, but the side effects produced by their intermediate or metabolized compounds are unknown. Up to now, there has been little information about the influence of authentic NO on Ca2+ handling in human platelets.
To explore the mechanism by which NO affects Ca2 + homeostasis in human platelets, we have investigated the direct effects ofauthentic NO on basal cytosolic [Ca2 +] levels and its influence on Ca2 + mobilization from internal stores, in the absence ofCa2 + influx. To this end, we have compared the various types of Ca2+ responses in human platelets induced by receptor occupancy versus inhibition of the Ca2+-ATPase pump. Two structurally unrelated compounds, the sesquiterpene lactone tumour promoter, thapsigargin (Tg) and the benzohydroquinone derivative, 2,5-di-(t-butyl)-1,4-benzohydroquinone (t-BuBHQ), were used ' Author for correspondence.
as specific inhibitors of the sarco/endoplasmic reticulum Ca2+-ATPases (SERCA pumps) (Papp et al., 1992) . These compounds elevate cytosolic [Ca2+] by inhibiting Ca2+ reuptake into the dense tubular system (Thastrup, 1987; Thastrup et al., 1990) .
Methods

Platelet preparation
Blood samples were collected between 08 h 00 min and 10 h 00 min from healthy subjects ofeither sex, aged between 20 and 45 years after an overnight fast. They had not taken any medications for at least 10 days. Venous blood was mixed with acid-citrate dextrose (ACD) anticoagulant at a ratio of9: 1 (vol/ vol) (2.73% citric acid, 4.48% trisodium citrate and 2% glucose). Platelet-rich plasma (PRP) was obtained by centrifugation at a maximum acceleration of 530 g for 5 min at 20°C. All platelet measurements were performed within 3 h ofblood sampling.
Nitric oxide measurement NO standards were prepared by serial dilutions of saturated NO solutions, as previously described (Lantoine et al., 1995b) . Saturated NO solutions were prepared under oxygen-free conditions by successive bubbling with argon for 20 min, then with pure NO gas (Aldrich) for 20 min. They were kept under NO atmosphere until use. Standards were made fresh for each experiment and kept in a glass flask with a thick rubber septum at 4°C. After the initial 20 min, the NO saturated solution was stable for more than 5 h and its concentration averaged 1-2 mM. Dilutions of the saturated solution were made with deoxygenated water. The concentrations of saturated and diluted NO solutions were assessed by spectrophotometric measurement with the Griess reagent (Green et al., 1982) and controlled by differential pulse amperometry with porphyrinBrifish Journal of Pharmacology (1996 Pharmacology ( ) 119, 1361 Pharmacology ( -1366 and nafion-coated electrodes built in our laboratory (Lantoine et al., 1995a) . All electrochemical studies were performed with the three-electrode potentiostatic system Biopulse made by Tacussel (Lantoine et al., 1995a Figure 4b . Since thapsigargin affects platelet Ca2+ handling in part through the synthesis of thromboxane A2 (TXA2) (Brune & Ullrich, 1991) , platelets were treated with the specific thromboxane-receptor antagonist, SQ 29548. In platelets treated with 5 gM SQ 29548 which blocks the self-amplification mechanism, the transient [Ca2+]i response induced by thapsigargin was decreased by 50+2% (n=4, P<0.001) (Figure 4a, trace 3 ). Under these conditions, the thapsigargin-elicited Ca2+ release was comparable to that of tBuBHQ, another inhibitor of sarco/endoplasmic reticulum Ca2+-ATPase (144+13 vs 135+3 nM, n=4 for each). Combined pretreatment with NO and SQ 29548 totally suppressed the transient [Ca2+] , peak evoked by thapsigargin, similar to that obtained with NO alone (Figure 4a , trace 4).
Stimulation by thrombin of thapsigargin-treated cells caused a dramatic decrease in Ca2+ release when compared to the first thapsigargin signal (Figure 4a , trace 1) or to that obtained with thrombin alone as the first signal (Figure 2a, Experiments were performed as described in (a) To define the effect of NO on the modulation of the Ca2+ ATPase pump activities better, its influence on the effect of tBuBHQ was investigated. As illustrated in Figure 5 
Discussion
The present study was designed to investigate the effects of authentic NO on Ca2+ mobilization in human platelets. It demonstrates that, in the absence of Ca2+ influx, NO (i) increases basal cytosolic [Ca2+] level in unstimulated platelets, (ii) attenuates the Ca2+ mobilization evoked either by thrombin and thromboxane A2 or by thapsigargin and tBuBHQ, the SERCA pump inhibitors, and (iii) blocks the self-amplification system involving thromboxane A2 formation. To our knowledge, such effects of NO on Ca2 + homeostasis in intact human platelets have not previously been demonstrated.
The recent observation that NO inhibits the active Ca2+ uptake into platelet membrane vesicles led us to check whether it could also increase the cytosolic Ca2 + concentration, as the well-known inhibitors of the SERCA pumps do (Thastrup, 1987; Thastrup et al., 1990; Papp et al., 1992) . A significant rise in [Ca2+] was indeed observed. It averaged 48% of the basal value and was more pronounced when the initial platelet [Ca2+]i level was low. A NO-mediated rise in the cytosolic [Ca2+] has also been described in other cell types including interstitial cells from canine colon (Publicover et al., 1993) , rat pancreatic fl-cells (Willmott et al., 1995) , intact sea urchin eggs (Willmott et al., 1996) and cultured nodose ganglion neurones from rabbits (Sato et al., 1996) . In cells possessing I . =24=zzi ryanodyne-sensitive Ca2+ channels, this Ca2+ rise can be partially due to the production of cyclic ADP-ribose, a Ca2+ mobilizing agent (Publicover et al., 1993; Willmott et al., 1995; . The presence of a ryanodine receptor mediated Ca21-induced Ca2+-release has not been established in platelets. The precise mechanism by which NO induced Ca2+ increase in human platelets remains therefore to be elucidated. The profile of the Ca2+ increase was markedly different from those observed after inhibition of SERCA pumps. It could be explained either by NO-induced concomitant reductions of the Ca2+ leak and Ca2+ pump activities, by a guanosine 3': 5'-cyclic monophosphate (cyclicGMP)-dependent stimulation of the plasma membrane Ca2+ pump or by an, as yet, unidentified NO-mediated Ca2+ mobilizing pathway. A NO inhibitory effect on ATP production, similar to that found by Borutaite & Brown (1996) can hardly be responsible for these alterations of Ca2+ movements and can be excluded, as indicated by the unchanged kinetics of Ca2+ return towards basal levels after thrombin stimulation (Figure 2a) . NO-donors have been shown to inhibit the platelet aggregation and Ca2+ mobilization induced by thrombin, ADP or the endoperoxide analogue U-46619 (Radomski et al., 1990; Nguyen et al., 1991; Durante et al., 1992; Geiger et al., 1994) . Similar platelet inhibitory effects were also obtained with cyclic GMP-elevating agents (Nakashima et al., 1986; Nguyen et al., 1991; Geiger et al., 1994; Gagnet et al., 1996) . These observations suggest that the inhibition of platelet function can be attributed mainly to the NO-mediated rise in cyclic GMP, through the inhibition ofagonist-evoked phospholipase C activation and Ca2+ mobilization from IP3-sensitive stores. Our data agree with this proposal that NO strongly decreases the thrombin-evoked Ca2+ discharge from intracellular stores. This inhibition could be caused by one or more independent mechanisms including an increase in platelet cyclic GMP levels. (Brune & Ullrich, 1991; Authi et al., 1993 and suppresses thromboxane generation in thrombin-stimulated human platelets (Sane et al., 1989 (Publicover et al., 1993; Willmott et al., 1995; Sato et al., 1996) questions the physiological significance of these NO effects on the NO-elicited Ca2+ increase. When the actual NO concentration available in the platelet suspension was controlled throughout the experiment by a NO-sensitive electrode and differential pulse amperometry, it was found to decrease from 5 to 2 gM within seconds after addition, and then to disappear slowly with an apparent half-life of approximately 400 s (unpublished data). A low NO concentration (0.1 gM) was also capable of significantly decreasing the initial rate of thapsigargin-induced Ca2+ rise. This level resembles those produced by stimulated endothelial cells (Tsukahara et al., 1993; Kanai et al., 1995) and could therefore be relevant.
In conclusion, nitric oxide increases basal [Ca2+] in unstimulated platelets and decreases Ca2+ discharge from stores sensitive to receptor stimulation or to Ca2+-ATPase inhibition.
In addition, nitric oxide behaves as an inhibitor of the thromboxane A2 pathway responsible for the self-amplification system.
A better characterization ofthe NO-sensitive Ca2+ pools should contribute to the understanding ofthe physiological regulation of platelet reactivity. All these NO properties could participate in its inhibitory effects on agonist-induced platelet release ofvaoactive substances and growth factors, which participate in the development of intimal hyperplasia and atherosclerosis.
